Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Critical Care
Published in: Critical Care 2/2006

01-04-2006 | Review

Clinical review: Specific aspects of acute renal failure in cancer patients

Authors: Michael Darmon, Magali Ciroldi, Guillaume Thiery, Benoît Schlemmer, Elie Azoulay

Published in: Critical Care | Issue 2/2006

Login to get access

Abstract

Acute renal failure (ARF) in cancer patients is a dreadful complication that causes substantial morbidity and mortality. Moreover, ARF may preclude optimal cancer treatment by requiring a decrease in chemotherapy dosage or by contraindicating potentially curative treatment. The pathways leading to ARF in cancer patients are common to the development of ARF in other conditions. However, ARF may also develop due to etiologies arising from cancer treatment, such as nephrotoxic chemotherapy agents or the disease itself, including post-renal obstruction, compression or infiltration, and metabolic or immunological mechanisms. This article reviews specific renal disease in cancer patients, providing a comprehensive overview of the causes of ARF in this setting, such as treatment toxicity, acute renal failure in the setting of myeloma or bone marrow transplantation.
Literature
1.
Lanore JJ, Brunet F, Pochard F, Bellivier F, Dhainaut JF, Vaxelaire JF, Giraud T, Dreyfus F, Dreyfuss D, Chiche JD, et al.: Hemo-dialysis for ARF in patients with hematologic malignancies. Crit Care Med 1991, 19: 346-351.CrossRefPubMed
2.
Benoit DD, Depuydt PO, Vandewoude KH, Offner FC, Boterberg T, De Cock CA, Noens LA, Janssens AM, Decruyenaere JM: Outcome in critically ill medical patients treated with renal replacement therapy for acute renal failure: comparison between patients with and those without haematological malignancies. Nephrol Dial Transplant 2005, 20: 552-558. 10.1093/ndt/gfh637CrossRefPubMed
3.
Azoulay E, Recher C, Alberti C, Soufir L, Leleu G, Le Gall JR, Fermand JP, Schlemmer B: Changing use of intensive care for hematological patients: the example of multiple myeloma. Intensive Care Med 1999, 25: 1395-1401. 10.1007/s001340051087CrossRefPubMed
4.
Azoulay E, Moreau D, Alberti C, Leleu G, Adrie C, Barboteu M, Cottu P, Levy V, Le Gall JR, Schlemmer B: Predictors of short-term mortality in critically ill patients with solid malignancies. Intensive Care Med 2000, 26: 1817-1823. 10.1007/s001340051350CrossRefPubMed
5.
Darmon M, Thiery G, Ciroldi M, de Miranda S, Galicier L, Raffoux E, Le Gall JR, Schlemmer B, Azoulay E: Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy. Crit Care Med 2005, 33: 2488-2493. 10.1097/01.CCM.0000181728.13354.0ACrossRefPubMed
6.
Bagshaw SM, Laupland KB, Doig CJ, Mortis G, Fick GH, Mucen-ski M, Godinez-Luna T, Svenson LW, Rosenal T: Prognosis for long-term survival and renal recovery in critically ill patients with severe acute renal failure: a population-based study. Crit Care 2005, 9: R700-R709. 10.1186/cc3879PubMedCentralCrossRefPubMed
7.
Munker R, Hill U, Jehn U, Kolb HJ, Schalhorn A: Renal complications in acute leukemias. Haematologica 1998, 83: 416-421.PubMed
8.
Azoulay E, Fieux F, Moreau D, Thiery G, Rousselot P, Parrot A, Le Gall JR, Dombret H, Schlemmer B: Acute monocytic leukemia presenting as acute respiratory failure. Am J Respir Crit Care Med 2003, 167: 1329-1333. 10.1164/rccm.200206-554OCCrossRefPubMed
9.
Benoit DD, Depuydt PO, Vandewoude KH, Offner FC, Boterberg T, De Cock CA, Noens LA, Janssens AM, Decruyenaere JM: Outcome of severely ill patients with haematological malignancies who received intravenous chemotherapy in the intensive care unit. Intensive Care Med 2006, 32: 93-99. 10.1007/s00134-005-2836-5CrossRefPubMed
10.
11.
Jeha S: Tumor lysis syndrome. Semin Hematol 2001, (Suppl 10):4-8. 10.1016/S0037-1963(01)90037-X
12.
Kalemkerian GP, Darwish B, Varterasian ML: Tumor lysis syndrome in small cell carcinoma and other solid tumors. Am J Med 1997, 103: 363-367. 10.1016/S0002-9343(97)00153-8CrossRefPubMed
13.
Pui CH: Urate oxidase in the prophylaxis or treatment of hyperuricemia: the United States experience. Semin Hematol 2001, (Suppl 10):13-21. 10.1016/S0037-1963(01)90039-3
14.
Baeksgaard L, Sorensen JB: Acute tumor lysis syndrome in solid tumors – a case report and review of the literature. Cancer Chemother Pharmacol 2003, 51: 187-192.PubMed
15.
Hebert LA, Lemann J Jr, Petersen JR, Lennon EJ: Studies of the mechanism by which phosphate infusion lowers serum calcium concentration. J Clin Invest 1966, 45: 1886-1894.PubMedCentralCrossRefPubMed
16.
Davidson MB, Thakkar S, Hix JK, Bhandarkar ND, Wong A, Schreiber MJ: Pathophysiology, clinical consequences, and treatment of tumor lysis syndrome. Am J Med 2004, 116: 546-554. 10.1016/j.amjmed.2003.09.045CrossRefPubMed
17.
18.
Rota S, Mougenot B, Baudouin B, De Meyer-Brasseur M, Lemaitre V, Michel C, Mignon F, Rondeau E, Vanhille P, Verroust P, et al.: Multiple myeloma and severe renal failure: a clinico-pathologic study of outcome and prognosis in 34 patients. Medicine (Baltimore) 1987, 66: 126-137.CrossRef
19.
Alexanian R, Barlogie B, Dixon D: Renal failure in multiple myeloma. Pathogenesis and prognostic implications. Arch Intern Med 1990, 150: 1693-1695. 10.1001/archinte.150.8.1693CrossRefPubMed
20.
21.
Clark WF, Stewart AK, Rock GA, Sternbach M, Sutton DM, Barrett BJ, Heidenheim AP, Garg AX, Churchill DN, the Canadian Apheresis Group: Plasma exchange when myeloma presents as acute renal failure: a randomized, controlled trial. Ann Intern Med 2005, 143: 777-784.CrossRefPubMed
22.
Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, Casassus P, Maisonneuve H, Facon T, Ifrah N, et al.: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996, 335: 91-97. 10.1056/NEJM199607113350204CrossRefPubMed
23.
Lee CK, Zangari M, Barlogie B, Fassas A, van Rhee F, Thertulien R, Talamo G, Muwalla F, Anaissie E, Hollmig K, Tricot G: Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotrans-plant. Bone Marrow Transplant 2004, 33: 823-828. 10.1038/sj.bmt.1704440CrossRefPubMed
24.
Kapoor M, Chan GZ: Malignancy and renal disease. Crit Care Clin 2001, 17: 571-598. viii 10.1016/S0749-0704(05)70199-8CrossRefPubMed
25.
Kwaan HC, Gordon LI: Thrombotic microangiopathy in the cancer patient. Acta Haematol 2001, 106: 52-56. 10.1159/000046589CrossRefPubMed
26.
Gordon LI, Kwaan HC: Cancer- and drug-associated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Semin Hematol 1997, 34: 140-147.PubMed
27.
Oleksowicz L, Bhagwati N, DeLeon-Fernandez M: Deficient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies. Cancer Res 1999, 59: 2244-2250.PubMed
28.
Chappell ME, Keeling DM, Prentice HG, Sweny P: Haemolytic uraemic syndrome after bone marrow transplantation: an adverse effect of total body irradiation? Bone Marrow Transplant 1988, 3: 339-347.PubMed
29.
Sarode R, McFarland JG, Flomenberg N, Casper JT, Cohen EP, Drobyski WR, Ash RC, Horowitz MM, Camitta B, Lawton C, et al.: Therapeutic plasma exchange does not appear to be effective in the management of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome following bone marrow transplantation. Bone Marrow Transplant 1995, 16: 271-275.PubMed
30.
Noel C, Hazzan M, Noel-Walter MP, Jouet JP: Renal failure and bone marrow transplantation. Nephrol Dial Transplant 1998, 13: 2464-2466. 10.1093/ndt/13.10.2464CrossRefPubMed
31.
Rock GA, Shumak KH, Buskard NA, Bushard NA, Blanchette VS, Kelton JG, Nair RC, Spasoff RA: Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. N Engl J Med 1991, 325: 393-397.CrossRefPubMed
32.
Penne F, Vignau C, Auburtin M, Moreau D, Zahar JR, Coste J, Heshmati F, Mira JP: Outcome of severe adult thrombotic microangiopathies in the intensive care unit. Intensive Care Med 2005, 31: 71-78. 10.1007/s00134-004-2505-0CrossRef
33.
Allford SL, Hunt BJ, Rose P, Machin SJ, Haemostasis and Thrombosis Task Force, Committee for Standards in Haematology: Guidelines on the diagnosis and management of thrombotic microangiopathic haemolytic anaemia. Br J Haematol 2003, 120: 556-573. 10.1046/j.1365-2141.2003.04049.xCrossRefPubMed
34.
Arany I, Safirstein RL: Cisplatin nephrotoxicity. Semin Nephrol 2003, 23: 460-464. 10.1016/S0270-9295(03)00089-5CrossRefPubMed
35.
Schuchter LM, Hensley ML, Meropol NJ, Winer EP, American Society of Clinical Oncology Chemotherapy and Radiotherapy Expert Panel: 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002, 20: 2895-2903. 10.1200/JCO.2002.04.178CrossRefPubMed
36.
Widemann BC, Balis FM, Kempf-Bielack B, Bielack S, Pratt CB, Ferrari S, Bacci G, Craft AW, Adamson PC: High-dose metho-trexate-induced nephrotoxicity in patients with osteosarcoma. Cancer 2004, 100: 2222-2232. 10.1002/cncr.20255CrossRefPubMed
37.
Buchen S, Ngampolo D, Melton RG, Hasan C, Zoubek A, Henze G, Bode U, Fleischhack G: Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br J Cancer 2005, 92: 480-487.PubMedCentralPubMed
38.
Flombaum CD, Meyers PA: High-dose leucovorin as sole therapy for methotrexate toxicity. J Clin Oncol 1999, 17: 1589-1594.PubMed
39.
Bedi A, Miller CB, Hanson JL, Goodman S, Ambinder RF, Charache P, Arthur RR, Jones RJ: Association of BK virus with failure of prophylaxis against hemorrhagic cystitis following bone marrow transplantation. J Clin Oncol 1995, 13: 1103-1109.PubMed
40.
Suarez A, McDowell H, Niaudet P, Comoy E, Flamant F: Long-term follow-up of ifosfamide renal toxicity in children treated for malignant mesenchymal tumors: an International Society of Pediatric Oncology report. J Clin Oncol 1991, 9: 2177-2182.PubMed
41.
Zager RA, O'Quigley J, Zager BK, Alpers CE, Shulman HM, Gamelin LM, Stewart P, Thomas ED: ARF following bone marrow transplantation: a retrospective study of 272 patients. Am J Kidney Dis 1989, 13: 210-216.CrossRefPubMed
42.
Merouani A, Shpall EJ, Jones RB, Archer PG, Schrier RW: Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer. Kidney Int 1996, 50: 1026-1031.CrossRefPubMed
43.
Parikh CR, McSweeney PA, Korular D, Ecder T, Merouani A, Taylor J, Slat-Vasquez V, Shpall EJ, Jones RB, Bearman SI, Schrier RW: Renal dysfunction in allogeneic hematopoietic cell transplantation. Kidney Int 2002, 62: 566-573. 10.1046/j.1523-1755.2002.00455.xCrossRefPubMed
44.
45.
Kessinger A, Schmit-Pokorny K, Smith D, Armitage J: Cryop-reservation and infusion of autologous peripheral blood stem cells. Bone Marrow Transplant 1990, (Suppl 1):25-27.
46.
Davis JM, Rowley SD, Braine HG, Piantadosi S, Santos GW: Clinical toxicity of cryopreserved bone marrow graft infusion. Blood 1990, 75: 781-786.PubMed
47.
McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Hardin BJ, Shulman HM, Clift RA: Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993, 118: 255-267.CrossRefPubMed
48.
Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hop-pensteadt D, Elias AD, Antin JH, Soiffer R, Spitzer T, et al.: Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and mul-tisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002, 100: 4337-4343. 10.1182/blood-2002-04-1216CrossRefPubMed
49.
Leung AY, Mak R, Lie AK, Yuen KY, Cheng VC, Liang R, Kwong YL: Clinicopathological features and risk factors of clinically overt haemorrhagic cystitis complicating bone marrow transplantation. Bone Marrow Transplant 2002, 29: 509-513. 10.1038/sj.bmt.1703415CrossRefPubMed
50.
Comar M, D'Agaro P, Andolina M, Maximova N, Martini F, Tognon M, Campello C: Hemorrhagic cystitis in children undergoing bone marrow transplantation: a putative role for simian virus 40. Transplantation 2004, 78: 544-548. 10.1097/01.TP.0000136257.02830.29CrossRefPubMed
51.
Mori K, Yoshihara T, Nishimura Y, Uchida M, Katsura K, Kawase Y, Hatano I, Ishida H, Chiyonobu T, Kasubuchi Y, et al.: ARF due to adenovirus-associated obstructive uropathy and necrotizing tubulointerstitial nephritis in a bone marrow transplant recipient. Bone Marrow Transplant 2003, 31: 1173-1176. 10.1038/sj.bmt.1704077CrossRefPubMed
Metadata
Title
Clinical review: Specific aspects of acute renal failure in cancer patients
Authors
Michael Darmon
Magali Ciroldi
Guillaume Thiery
Benoît Schlemmer
Elie Azoulay
Publication date
01-04-2006
Publisher
BioMed Central
Published in
Critical Care / Issue 2/2006
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc4907

Other articles of this Issue 2/2006

Critical Care 2/2006 Go to the issue

Commentary

The choice of catecholamines in septic shock: more and more good arguments to strengthen the known position, but don't lose the faith!

Journal club critique

Demonstrating the benefit of medical emergency teams (MET) proves more difficult than anticipated

Research

Plasma DNA concentration as a predictor of mortality and sepsis in critically ill patients

Research

Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies

Commentary

Epidemiology studies in critical care

Research

Circulating inflammatory mediators and organ dysfunction after cardiovascular surgery with cardiopulmonary bypass: a prospective observational study